School of Medicine Medical Sciences & Nutrition. Institute of Medical Sciences. University of Aberdeen. Aberdeen, UK.
Princess Margaret Rose Orthopaedic Hospital, Edinburgh, UK.
J Hand Surg Eur Vol. 2023 Sep;48(8):699-709. doi: 10.1177/17531934231177425. Epub 2023 May 24.
This review article provides a comprehensive overview of thalidomide upper limb embryopathy including updates about its pathogenesis, a historical account of the management of the paediatric thalidomide patient, experience with management of the adult patient, as well as creating awareness about early onset age-related changes associated with limb differences. Despite its withdrawal from the market in November 1961, novel discoveries have meant thalidomide is licensed again and currently still in use to treat a variety of conditions, including inflammatory disorders and some cancers. Yet, if not used safely, thalidomide still has the potential to cause damage to the embryo. Recent work identifying thalidomide analogues that retain clinical benefits yet without the harmful effects are showing great promise. Understanding the problems thalidomide survivors face as they age can allow surgeons to support their unique healthcare issues and translate these principles of care to other congenital upper limb differences.
这篇综述文章全面概述了沙利度胺上肢畸形，包括其发病机制的最新进展、儿童沙利度胺患者管理的历史回顾、成人患者管理的经验，以及对与肢体差异相关的早期年龄相关变化的认识。尽管沙利度胺已于 1961 年 11 月从市场上撤出，但新的发现意味着沙利度胺再次获得许可，目前仍在用于治疗多种疾病，包括炎症性疾病和某些癌症。然而，如果使用不当，沙利度胺仍有可能对胚胎造成损害。最近的研究发现，保留了临床益处但没有不良影响的沙利度胺类似物具有很大的前景。了解沙利度胺幸存者随着年龄增长所面临的问题，可以让外科医生能够支持他们独特的医疗保健问题，并将这些护理原则转化为其他先天性上肢差异。
